Description
Specifications
- Form: White lyophilized powder, dual-peptide blend
- Standard vial size: 10mg total (5mg CJC-1295 no DAC / 5mg Ipamorelin)
- Purity: ≥99% each peptide (HPLC & Mass Spec verified)
- Storage: Store lyophilized powder at -20°C; refrigerate at 2–8°C once reconstituted, use within 20-30 days
Overview
This blend combines a GHRH receptor agonist (CJC-1295 without DAC) with a selective GHS-R1a agonist (Ipamorelin) in a single vial, reflecting one of the most frequently studied combination protocols in growth-hormone axis research.
Mechanism & Research Findings
Because GHRH and ghrelin-receptor pathways stimulate GH release through independent, non-competing mechanisms, co-administration in animal models has been shown to produce a synergistic (greater than additive) GH pulse compared to either compound alone. This blend is formulated to let researchers study that synergy directly without needing to separately reconstitute and combine two vials, standardizing dosing ratios across experimental replicates.
Research Applications
- GHRH/GHS-R1a synergy studies
- Dual-pathway growth hormone axis modeling
- Comparative single-agent vs. combination-protocol research
For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.


Reviews
There are no reviews yet.